In subjects over 40 years of age, visual acuity of the dominant eye after VDT work demonstrated a stronger protective effect
BGG World (BGG) has shared the publication of a peer-reviewed human clinical trial demonstrating AstaZine Natural Astaxanthin’s ability to improve visual function in healthy adults.
The study enrolled 60 subjects working on visual display terminals (VDT) and ingesting 9mg per day of AstaZine Natural Astaxanthin or placebo over six weeks.
As we age, doctors believe that key muscles in our eyes lose strength which, in turn, leads to a reduction in our ability to see detail
In subjects over 40 years of age, visual acuity of the dominant eye after VDT work demonstrated a stronger protective effect in the Astaxanthin group versus the placebo group, suggesting that Astaxanthin reduces oxidative stress caused by visual display terminal work.
“This is the second publication for visual health which used AstaZine”, said Yanmei Li, PhD, BGG’s Global Chief Scientific Officer. “As we age, doctors believe that key muscles in our eyes lose strength which, in turn, leads to a reduction in our ability to see detail. This is particularly pronounced in people overusing computers and smartphones. Fortunately, supplementing with AstaZine is an effective way to combat this condition that affects so many of us in today’s world.”
BGG is a global B2B supplier of ingredients sourced from nature that improve consumer wellness. The company’s portfolio originates from algae, fruits and plants. BGG employs a staff of approximately 450, has six production sites, international branches in North America, Japan, China, and Switzerland, and manages sales in over 100 countries.